Biologic Treatment for Hidradenitis Suppurativa

Kelsey S. Flood; Martina L. Porter; Alexa B. Kimball


Am J Clin Dermatol. 2019;20(5):625-638. 

In This Article

Laboratory Monitoring With Biologics

There are no specific guidelines dictating management of the HS patient on biologics. Prior to initiating a patient on a biologic, we perform screening labs for hepatitis B, hepatitis C, and tuberculosis infections. Tuberculosis screening should be repeated annually. Routine drug monitoring for the HS patient managed with a biologic includes a chemistry panel and complete blood count with differential and liver function tests obtained at baseline and repeated every 6 months.